<<Do you believe that the approval risk for this drug is the same or worse than that of the above-mentioned chemo agents? Not likely, according to the human trials done with Fluosol to date.Again Fluosol and Pher02 share the identical active ingredient.<<
Actually the risk for approval is much worse for Pher02 than for chemotherapy products. This can be easily understood by the fact that while numerous chemotherapy products have been approved by the FDA, not one blood substitute product has yet been approved.
>>Please stop creating the impression that no one will see profit from this stock for years, or that approval is to be an unlikely process. You and I both know better.
Tell us about the companies and products in which you have been involved, and let us know what leads you to beleve that Pher02 has a difficult, long road ahead. <<
Just as you are creating the impression that investors will see a handsome profit from this stock, Mr. Forthright has the right to create an alternate impression. I think rational individuals can come to either conclusion. Both opinions are valid, so I don't see why either of you should stop.
IMO, approval IS unlikely, which is simply evidenced by the fact that companies have spent billions of dollars over many years attempting to bring a blood substitute to market and have failed to do so. Why should we believe this little OTCBB company is likely to do so.
For the very reason that no other blood substitute has made it to market, it is quite logical to believe that Pher02 has a long and difficult road ahead of it, even if they should secure funding from someone like LLY or PFE.
Finally, let me say that I do believe there may be substantial upside potential for this stock. But not because the product is likely to be ultimately approved by the FDA or because the road will not be long, expensive and difficult. Much more likely because they may garner support from a larger partner. But that will most likely have to wait until they are well into P1, IMO, which could take a year or longer. However, as you point out, even success in animal trials could lead to considerable interest. |
